TY - JOUR
T1 - Long-Term fatigue and quality of life among epithelial ovarian cancer survivors
T2 - A GINECO case/control VIVROVAIRE i study
AU - Joly, F.
AU - Ahmed-Lecheheb, D.
AU - Kalbacher, E.
AU - Heutte, N.
AU - Clarisse, B.
AU - Grellard, J. M.
AU - Gernier, F.
AU - Berton-Rigaud, D.
AU - Tredan, O.
AU - Fabbro, M.
AU - Savoye, A. M.
AU - Kurtz, J. E.
AU - Alexandre, J.
AU - Follana, P.
AU - Delecroix, V.
AU - Dohollou, N.
AU - Roemer-Becuwe, C.
AU - De Rauglaudre, G.
AU - Lortholary, A.
AU - Prulhiere, K.
AU - Lesoin, A.
AU - Zannetti, A.
AU - N'Guyen, S.
AU - Trager-Maury, S.
AU - Chauvenet, L.
AU - Abadie Lacourtoisie, S.
AU - Gompel, A.
AU - Lhommé, C.
AU - Floquet, A.
AU - Pautier, P.
N1 - Publisher Copyright:
© 2019 The Author(s) 2019. Published by Oxford University Press on behalf of the European Society for Medical Oncology. All rights reserved.
PY - 2019/5/1
Y1 - 2019/5/1
N2 - Background: Few data are available on long-Term fatigue (LTF) and quality of life (QoL) among epithelial ovarian cancer survivors (EOCS). In this case-control study, we compared LTF, symptoms and several QoL domains in EOCS relapse-free ≥3 years after first-line treatment and age-matched healthy women. Patients and methods: EOCS were recruited from 25 cooperative GINECO centers in France. Controls were randomly selected from the electoral rolls. All participants completed validated self-reported questionnaires: fatigue (FACIT-F), QoL (FACT-G/O), neurotoxicity (FACT-Ntx), anxiety/depression (HADS), sleep disturbance (ISI), and physical activity (IPAQ). Severe LTF (SLTF) was defined as a FACIT-F score <37/52. Univariate and multivariate logistic regressions were conducted to analyze SLTF and its influencing factors in EOCS. Results: A total of 318 EOCS and 318 controls were included. EOCS were 63-year-old on average, with FIGO stage I/II (50%), III/IV (48%); 99% had received platinum and taxane chemotherapy, with an average 6-year follow-up. There were no differences between the two groups in socio-demographic characteristics and global QoL. EOCS had poorer FACIT-F scores (40 versus 45, P < 0.0001), lower functional well-being scores (18 versus 20, P = 0.0002), poorer FACT-O scores (31 versus 34 P < 0.0001), and poorer FACT-Ntx scores (35 versus 39, P < 0.0001). They also reported more SLTF (26% versus 13%, P = 0.0004), poorer sleep quality (63% versus 47%, P = 0.0003), and more depression (22% versus 13%, P = 0.01). Fewer than 20% of EOCS and controls exercised regularly. In multivariate analyses, EOCS with high levels of depression, neurotoxicity, and sleep disturbance had an increased risk of developing SLTF (P < 0.01). Conclusion: Compared with controls, EOCS presented similar QoL but persistent LTF, EOC-related symptoms, neurotoxicity, depression, and sleep disturbance. Depression, neuropathy, and sleep disturbance are the main conditions associated with severe LTF.
AB - Background: Few data are available on long-Term fatigue (LTF) and quality of life (QoL) among epithelial ovarian cancer survivors (EOCS). In this case-control study, we compared LTF, symptoms and several QoL domains in EOCS relapse-free ≥3 years after first-line treatment and age-matched healthy women. Patients and methods: EOCS were recruited from 25 cooperative GINECO centers in France. Controls were randomly selected from the electoral rolls. All participants completed validated self-reported questionnaires: fatigue (FACIT-F), QoL (FACT-G/O), neurotoxicity (FACT-Ntx), anxiety/depression (HADS), sleep disturbance (ISI), and physical activity (IPAQ). Severe LTF (SLTF) was defined as a FACIT-F score <37/52. Univariate and multivariate logistic regressions were conducted to analyze SLTF and its influencing factors in EOCS. Results: A total of 318 EOCS and 318 controls were included. EOCS were 63-year-old on average, with FIGO stage I/II (50%), III/IV (48%); 99% had received platinum and taxane chemotherapy, with an average 6-year follow-up. There were no differences between the two groups in socio-demographic characteristics and global QoL. EOCS had poorer FACIT-F scores (40 versus 45, P < 0.0001), lower functional well-being scores (18 versus 20, P = 0.0002), poorer FACT-O scores (31 versus 34 P < 0.0001), and poorer FACT-Ntx scores (35 versus 39, P < 0.0001). They also reported more SLTF (26% versus 13%, P = 0.0004), poorer sleep quality (63% versus 47%, P = 0.0003), and more depression (22% versus 13%, P = 0.01). Fewer than 20% of EOCS and controls exercised regularly. In multivariate analyses, EOCS with high levels of depression, neurotoxicity, and sleep disturbance had an increased risk of developing SLTF (P < 0.01). Conclusion: Compared with controls, EOCS presented similar QoL but persistent LTF, EOC-related symptoms, neurotoxicity, depression, and sleep disturbance. Depression, neuropathy, and sleep disturbance are the main conditions associated with severe LTF.
KW - cancer treatment
KW - chronic fatigue
KW - epithelial ovarian cancer
KW - long-Term survivorship
KW - quality of life
UR - http://www.scopus.com/inward/record.url?scp=85067465678&partnerID=8YFLogxK
U2 - 10.1093/annonc/mdz074
DO - 10.1093/annonc/mdz074
M3 - Article
C2 - 30851097
AN - SCOPUS:85067465678
SN - 0923-7534
VL - 30
SP - 845
EP - 852
JO - Annals of Oncology
JF - Annals of Oncology
IS - 5
M1 - mdz074
ER -